{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:22:07Z","timestamp":1792671727677,"version":"4.5.0"},"reference-count":19,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: Prostate-specific antigen (PSA) concentration is considered an important prognostic marker, with rapid and large reductions associated with a favorable outcome and prolonged survival. Material and Methods: We conducted a single institution and tertiary cancer center retrospective analysis of metastatic hormone-sensitive prostate cancer (mHSPC) patients undergoing active treatment at Division of Oncology and Radiotherapy, University Hospital Dubrava, between December 2022 and August 2025. This study aimed to assess the association between the PSA levels and survival in mHSPC patients undergoing active treatment. Results: A total of 42 (59.2%) in our cohort achieved UL PSA levels, while 29 patients (40.8%) had PSA levels &gt; 0.2 ng\/mL. Cox regression analysis identified age &gt; 71 years at the diagnosis of mHSPC and UL PSA levels as statistically significant factors associated with favorable outcome. Conclusions: Our real-world data demonstrated that UL PSA is a favorable prognostic factor associated with prolonged survival and improved prognosis. However, we identified patients achieving UL PSA levels, who experienced radiographic progression. Our finding suggests that even among \u201cbest\u201d PSA responders, some might develop resistant clones that manifest via imaging progression without PSA rise.<\/jats:p>","DOI":"10.3390\/medicina61122110","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:25:16Z","timestamp":1764239116000},"page":"2110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Significance of Ultralow (UL) Prostate-Specific Antigen (PSA) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Single Institution and Tertiary Cancer Center Experience"],"prefix":"10.3390","volume":"61","author":[{"given":"Petar","family":"Suton","sequence":"first","affiliation":[{"name":"Division of Oncology and Radiotherapy, University Hospital Dubrava, Avenue Gojko \u0160u\u0161ak 6, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vi\u0161nja","family":"Gregov","sequence":"additional","affiliation":[{"name":"Division of Oncology and Radiotherapy, University Hospital Dubrava, Avenue Gojko \u0160u\u0161ak 6, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide plus androgen-deprivation therapy for metastatic castration-sensitive prostate cancer","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of enzalutamide plus androgen deprivation therapy versus placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"555","article-title":"Post-hoc analysis of the TITAN trial: Ultralow PSA response with apalutamide plus androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer","volume":"133","author":"Merseburger","year":"2024","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Abad, A., Belmonte, M., Ram\u00edrez Backhaus, M., Server G\u00f3mez, G., Cao Avellaneda, E., Moreno Alarc\u00f3n, C., L\u00f3pez Cubillana, P., Yago Gim\u00e9nez, P., de Pablos Rodr\u00edguez, P., and Juan Fita, M.J. (2024). Ultralow prostate-specific antigen (PSA) levels and improved oncological outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with Apalutamide: A real-world multicentre study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13206221"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e6817","DOI":"10.1097\/MD.0000000000006817","article-title":"PSA Declines and Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Retrospective Case-Report Study","volume":"96","author":"Bosso","year":"2017","journal-title":"Medicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2833622","DOI":"10.1001\/jamanetworkopen.2025.8751","article-title":"Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial","volume":"8","author":"Azad","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/iju.15615","article-title":"Prostate-Specific Antigen Kinetics in Asian Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide in the TITAN Trial: A Post Hoc Analysis","volume":"32","author":"Ye","year":"2025","journal-title":"Int. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with non-rising PSA in metastatic castration-resistant prostate cancer: Post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2024.42.4_suppl.151","article-title":"Radiographic Progression without PSA Progression in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Retrospective Analysis from the ENZAMET Trial (ANZUP 1304)","volume":"42","author":"Davis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.2025.43.5_suppl.213","article-title":"Radiographic Progression without PSA Progression in Advanced Prostate Cancer Patients","volume":"43","author":"Chaudhary","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/JCO.2022.40.16_suppl.5072","article-title":"Radiographic Progression in the Absence of Prostate-Specific Antigen (PSA) Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Post Hoc Analysis of ARCHES","volume":"40","author":"Armstrong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","article-title":"Radiographic Progression without Corresponding Prostate-Specific Antigen Progression in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial","volume":"8","author":"Fukuokaya","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"527.e9","DOI":"10.1016\/j.urolonc.2025.05.006","article-title":"PSA Kinetics and Predictors of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors","volume":"43","year":"2025","journal-title":"Urol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/12\/2110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:14:01Z","timestamp":1764242041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/12\/2110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["medicina61122110"],"URL":"https:\/\/doi.org\/10.3390\/medicina61122110","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}